TY  - JOUR
A1  - Zhou, Xiang
A1  - Steinhardt, Maximilian J.
A1  - Grathwohl, Denise
A1  - Meckel, Katharina
A1  - Nickel, Katharina
A1  - Leicht, Hans‐Benno
A1  - Krummenast, Franziska
A1  - Einsele, Hermann
A1  - Rasche, Leo
A1  - Kortüm, Klaus M.
T1  - Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
T2  - Cancer Medicine
N2  - Background
Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in RRMM.


Methods
We retrospectively analyzed data of 56 patients with RRMM who received Pom‐PAD‐Dara between September 2016 and May 2019.


Results
Patients were heavily pretreated with a median of four prior lines of therapy, including autologous and allogenic stem cell transplant in 50 (89%) and six (11%) patients, respectively. The overall response rate (ORR) was 78% and we observed partial remission, very good partial remission, and complete remission in 27 (48%), 13 (23%) and four (7%) patients, respectively. Median progression‐free survival was 7 months (95% CI, 3.3‐10.7) and the median overall survival was not reached at 24 months. Adverse events grade ≥ 3 were observed 41 (73%) patients and included neutropenia (n = 28, 50%), anemia (n = 22, 39%), thrombocytopenia (n = 21, 38%), and pneumonia (n = 6, 11%).


Conclusion
Pom‐PAD‐Dara represents a promising multiagent regimen in heavily pretreated RRMM patients with high ORR and an acceptable safety profile.
KW  - multiple myeloma
KW  - Pom‐PAD‐Dara
KW  - refractory
KW  - relapse
Y1  - 2020
UR  - https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/21802
UR  - https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-218029
VL  - 9
IS  - 16
ER  -